Johnson & Johnson (NYSE:JNJ) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Share on StockTwits

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the first quarter, Holdings Channel reports. The firm owned 1,039,519 shares of the company’s stock after buying an additional 40,509 shares during the quarter. Johnson & Johnson accounts for 1.3% of Zurcher Kantonalbank Zurich Cantonalbank’s investment portfolio, making the stock its 10th biggest holding. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Johnson & Johnson were worth $136,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Exchange Traded Concepts LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $31,000. University of Texas Texas AM Investment Managment Co. acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $31,000. Advocacy Wealth Management Services LLC lifted its stake in shares of Johnson & Johnson by 38.2% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 300 shares of the company’s stock worth $39,000 after acquiring an additional 83 shares during the period. Lion Street Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth $45,000. Finally, Joseph P. Lucia & Associates LLC lifted its stake in shares of Johnson & Johnson by 50.8% in the 1st quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock worth $49,000 after acquiring an additional 126 shares during the period. Hedge funds and other institutional investors own 67.66% of the company’s stock.

Several analysts have recently commented on the stock. UBS Group cut shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $163.00 to $160.00 in a research note on Tuesday, April 28th. Barclays raised their price objective on shares of Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Argus reiterated a “buy” rating and issued a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. SVB Leerink reduced their price objective on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Finally, Raymond James raised their price objective on shares of Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $163.47.

In other news, Director William D. Perez purchased 500 shares of the stock in a transaction dated Friday, March 13th. The stock was acquired at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the acquisition, the director now directly owns 16,030 shares in the company, valued at approximately $2,046,870.70. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.27% of the company’s stock.

NYSE:JNJ opened at $144.37 on Friday. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $146.81 and a two-hundred day moving average price of $142.30. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The company has a market capitalization of $386.52 billion, a P/E ratio of 19.10, a price-to-earnings-growth ratio of 3.19 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The firm had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. During the same period last year, the firm posted $2.10 EPS. The firm’s revenue for the quarter was up 3.3% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 7.68 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 annualized dividend and a yield of 2.80%. The ex-dividend date is Friday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 43.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is the LIBOR?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AE Wealth Management LLC Invests $384,000 in Sailpoint Technologies Holdings Inc
AE Wealth Management LLC Invests $384,000 in Sailpoint Technologies Holdings Inc
Johnson & Johnson  Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank
Johnson & Johnson Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank
Brooktree Capital Management Has $4.25 Million Stock Position in Johnson & Johnson
Brooktree Capital Management Has $4.25 Million Stock Position in Johnson & Johnson
Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Holdings in Wayfair Inc
Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Holdings in Wayfair Inc
Zurcher Kantonalbank Zurich Cantonalbank Grows Position in Coupa Software Inc
Zurcher Kantonalbank Zurich Cantonalbank Grows Position in Coupa Software Inc
First Trust Advisors LP Acquires 108,318 Shares of Dynatrace
First Trust Advisors LP Acquires 108,318 Shares of Dynatrace


© 2006-2020 Ticker Report